Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

Immutep believes its LAG-3 candidate eftilagimod alpha may have a path to approval in first-line head and neck cancer after ...

Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's immunotherapy Keytruda significantly slowed disease progression in patients with an ...

Following President Trump’s announcement on Monday of an executive order to cut prescription drug prices, experts share some of the most expensive medications.

There are many problems with the plan. It ignores the fact, for instance, that generic drugs, which make up 90% of ...

First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and ...

President Donald Trump has issued a new executive order giving pharmaceutical companies a 30-day window to voluntarily lower ...

Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck ...

Leap Therapeutics is laying off half of its staff as the company narrows the focus of its lead cancer drug against the ...

The FDA is currently reviewing Merck’s sBLA for Keytruda in head and neck cancer, with a target action date of June 23.

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.